Reta glucagon-like peptide-1 (GLP-1) receptor agonists provide a groundbreaking approach to diabetes management. These innovative therapies operate by mimicking the natural actions of GLP-1, a hormone produced by the gut in response to meals. By triggering GLP-1 receptors in the pancreas, these agents enhance insulin production and inhibit glucagon

The management of diabetes is with the emergence of exciting new therapies. Among these, Reta, GLP-1 receptor agonists, Retatrutide, and Trizepatide are gaining significant attention. These medications offer promising strategies for controlling blood sugar levels and potentially improve the lives of individuals living with diabetes. Reta| acts by